Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov 5:11:e2021340.
doi: 10.4322/acr.2021.340. eCollection 2021.

Mantle cell lymphoma presenting with lethal atraumatic splenic rupture

Affiliations
Case Reports

Mantle cell lymphoma presenting with lethal atraumatic splenic rupture

Frederick Eyerer et al. Autops Case Rep. .

Abstract

Mantle cell lymphoma is characterized by t(11;14) with CCND1-IGH fusion and manifests with a spectrum of disease ranging from relatively indolent to aggressive. Here, we present a case of pleomorphic mantle cell lymphoma with three fusion signals that presented with lethal atraumatic splenic rupture. We discuss on the implications of variant CCND1 signal patterns as well as the epidemiology and pathophysiology of atraumatic splenic rupture.

Keywords: Cyclin D; Lymphoma, Malignant; Lymphoma, Mantle-Cell; Splenic Rupture.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None.

Figures

Figure 1
Figure 1. CT imaging demonstrating splenomegaly with hemorrhage, splenic laceration, and perisplenic hematoma (red arrows). Lymphadenopathy was also noted on imaging (not shown).
Figure 2
Figure 2. Peripheral blood smear (Wright Giemsa, 100X) demonstrating pleomorphic atypical lymphocytes (red arrows).
Figure 3
Figure 3. Flow cytometric analysis showing a clonal population of kappa-restricted CD5+ B-cells that express FMC7 and bright CD20 and lack CD23 (Top row: black dots backgated on CD19+ events).
Figure 4
Figure 4. Dual fusion FISH for CCND1 and IGH, demonstrating a variant abnormal signal pattern with three copies of CCND1-IGH fusion (yellow signals).

Similar articles

Cited by

References

    1. Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94(6):710–725. doi: 10.1002/ajh.25487. - DOI - PubMed
    1. Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2018;181(5):703–706. doi: 10.1111/bjh.14699. - DOI - PubMed
    1. Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th. Lyon: International Agency for Research on Cancer; 2008. 439. (World Health Organization Classification of Tumours).
    1. Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647–1656. doi: 10.1182/blood-2018-03-791392. - DOI - PubMed
    1. Martín-Garcia D, Navarro A, Valdés-Mas R, et al. CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphoma. Blood. 2019;133(9):940–951. doi: 10.1182/blood-2018-07-862151. - DOI - PMC - PubMed

Publication types